Edition:
United States

Elekta AB (publ) (EKTAb.ST)

EKTAb.ST on Stockholm Stock Exchange

89.90SEK
7:04am EDT
Change (% chg)

-0.55kr (-0.61%)
Prev Close
90.45kr
Open
90.35kr
Day's High
90.90kr
Day's Low
89.80kr
Volume
411,341
Avg. Vol
1,081,375
52-wk High
95.90kr
52-wk Low
58.80kr

Latest Key Developments (Source: Significant Developments)

Varian Medical Systems and Elekta settle patent litigation
Monday, 3 Apr 2017 04:41pm EDT 

Elekta AB (Publ) : Varian Medical Systems and Elekta settle patent litigation . Varian Medical Systems - reached confidential settlement agreement with Elekta for patent litigation involving technology used for radiation oncology .Varian Medical Systems Inc - resolved dispute with no payments exchanged by plaintiffs and defendants and no future financial obligations.  Full Article

Elekta Q3 core EBITA lags expectations
Wednesday, 1 Mar 2017 01:42am EST 

Elekta Ab : Q3 EBITA. amounted to sek 325 m (335) before items affecting comparability of sek -58 m (-91) and bad debt losses of sek -1 m (-72). . Elekta ab Q3 gross order intake amounted to sek 3,653 m (2,616) . Says our activities related to transformation program are progressing and delivering in line with defined targets for cost savings and margins . Reuters poll: elekta q3 order intake was seen at 3,037 million sek, adjusted ebita at 443 million . Says interest in our paradigm shifting mr-linac continues to grow. We already have agreements for 12 systems . Says convinced will reach target of 75 orders before end of 2019 calendar year . Elekta says have initiated additional measures for improved performance in the us . Says transformation program is well under way and we do what we say by continuously improving our processes . Elekta ab says we have a strong order backlog going into Q4 and compared with same period last year we plan to deliver substantially more from backlog .Elekta ab says gross order intake in the North and South America region decreased 3 percent in the third quarter.  Full Article

Elekta receives 510(k) clearance for Venezia for treating advanced-stage gynecological cancers
Thursday, 2 Feb 2017 08:42am EST 

Elekta AB (Publ) :Elekta receives 510(k) clearance for Venezia, an image-guided brachytherapy applicator for treating advanced-stage gynecological cancers.  Full Article

Elekta CEO says in final talks for a number of MR-linac orders
Thursday, 1 Dec 2016 02:52am EST 

Elekta AB CEO Richard Hausmann to Reuters: says very good pipeline for mr-linac, in final negotiations for a number of contracts . says north america market is flattish or slightly growing, sees good momentum currently from stereotactic radio surgery and stereotactic body surgery applications Further company coverage: [EKTAb.ST] (Reporting By Anna Ringstrom) ((Anna.Ringstrom@thomsonreuters.com;)).  Full Article

Elekta Q2 core EBITA, order intake below consensus
Thursday, 1 Dec 2016 01:30am EST 

Elekta AB : q2 ebita. sek 391 m (451) before items affecting comparability of sek -117 m (-18) and bad debt losses sek -23 m (-7) . gross order intake amounted to sek 3,383 m (3,398) . Reuters poll: elekta q2 order intake was seen at 3,479 million sek, adjusted ebita at 450 million . says global market for radiation therapy is in essence stable, although we continue to see quarterly fluctuations . says measures for improvement in region north and south america are slowly yielding results . says gross orders returned to growth in q2 mainly driven by strong performance in our latin american operations . says in north and south america gross orders returned to growth in q2 mainly driven by strong performance in our latin american operations . ceo says my confidence in potential of our mr-linac is reinforced . says change of supply chain process to produce-to-order is now completed and had a negative one-off effect on net sales of sek 650 m for h1 .says demand in south america is growing, however, weak economic conditions throughout the region have slowed investments in new equipment.  Full Article

Elekta says on track to reach targets of transformation program
Monday, 26 Sep 2016 09:00am EDT 

Elekta AB : Says company is on track to reach targets of its transformation program .Says these targets include an EBITA margin of 20 percent in 2017/18; cost reductions of SEK 700 million, with full effect 2017/18; and a net working capital to sales ratio below five percent in 2016/17.  Full Article

Elekta Q1 core profit tops forecast
Thursday, 1 Sep 2016 01:30am EDT 

Elekta AB : Q1 EBITA, adjusted for items affecting comparability and bad debt losses, amounted to SEK 166 m (68) . Reuters poll: Elekta adjusted EBITA at SEK 80 million . Elekta Q1 gross order intake increased by 4 percent to SEK 2,662 m (2,569) . Q1 items affecting comparability was SEK -89 m (-30) and bad debt losses was SEK -6 m (-27) . Net sales decreased 16 percent to SEK 1,882 M (2,239) and 15 percent based on constant exchange rates . Says our target is to reduce cost base with SEK 700 m compared with 2014/15 and we are half way through process .Says order growth in china was particularly strong with an increase of 30 percent.  Full Article

Elekta core earnings undershoot, says first half of fiscal 2016/17 to be weak
Wednesday, 1 Jun 2016 01:30am EDT 

Elekta AB : Says board of directors proposes a dividend of sek 0.50 (0.50) per share for fiscal year 2015/16 and that dividend will be divided into two payments from now on . Q4 EBITA, adjusted for non-recurring items and bad debt losses, amounted to SEK 785 m (739). Non-Recurring items was SEK -459 m (-1) and bad debt losses was SEK -43 m (-138) . Q4 net order bookings increased 17 percent to sek 4,520 m (3,856) and increased 16 percent based on constant exchange rate . Reuters poll: Elekta Q4 order bookings were seen at SEK 4,303 million, adjusted EBITA at SEK 905 million, dividend per share SEK 0.72 . Says to further reduce inventories, will undertake temporary reduced production and shipment volume, with a one-off negative revenue impact estimated at about sek 500 m in first half of fiscal year 2016/17 . Says expects a weak result during first half of fiscal year 2016/17 . Says additional expected costs related to transformation are estimated to be approximately SEK 300 m and will be charged as a non-recurring item during fiscal 2016/17 . Says going forward Elekta will not provide a net sales outlook . Says targets for transformation program include reaching an EBIT margin of 20 percent in fiscal year 2017/18 .Says also includes to realize cost reductions of SEK 700 m with full effect from 2017/18.  Full Article

Elekta says Leksell Gamma Knife Icon cleared for use in Japan, US
Wednesday, 1 Jun 2016 01:30am EDT 

Elekta Publ AB :Elekta's Leksell Gamma Knife Icon cleared for use in Japan and United States.  Full Article

Elekta to pay 8.9 million euro in legal dispute
Tuesday, 24 May 2016 12:00pm EDT 

Elekta Publ Ab : Elekta to pay humediQ eur 8.9 million in legal dispute . An arbitration tribunal in London issued an award in a dispute between two Elekta group companies and humediQ GmbH . The tribunal determined that the Elekta companies did not validly terminate a 2011 agreement and that, as a result, they must pay humediQ approximately 8.9 million euro . In addition, Elekta will write off approximately 5 million euro connected to payments made under the agreement. .Says the negative result of approximately 14 million euro will be taken in the fourth quarter of Elekta's fiscal year 2015/16 as a non-recurring item.  Full Article

More From Around the Web

BRIEF-Varian Medical Systems and Elekta settle patent litigation

* Varian Medical Systems - reached confidential settlement agreement with Elekta for patent litigation involving technology used for radiation oncology